Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Stem Cell Research

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    March 2023
  1. NAKAGAWA-SAITO Y, Mitobe Y, Togashi K, Suzuki S, et al
    Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
    Anticancer Res. 2023;43:1131-1138.
    PubMed     Abstract available

    February 2023
  2. SANO Y, Kuwabara N, Nakagawa S, Toda Y, et al
    Hypoxia-adapted Multiple Myeloma Stem Cells Resist gammadelta-T-Cell-mediated Killing by Modulating the Mevalonate Pathway.
    Anticancer Res. 2023;43:547-555.
    PubMed     Abstract available

    December 2022
  3. STEINER N, Schober P, Willenbacher W, Kircher B, et al
    Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years.
    Anticancer Res. 2022;42:5825-5832.
    PubMed     Abstract available

    November 2022
  4. KOCH K, Osswald L, Miller I, Braitsch K, et al
    Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
    Anticancer Res. 2022;42:5431-5441.
    PubMed     Abstract available

    September 2022
  5. SUKPRASANSAP M, Chanvorachote P
    Evidence of Potential Plant-derived Compounds With Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches.
    Anticancer Res. 2022;42:4247-4258.
    PubMed     Abstract available

    July 2022
  6. ZHAO X, Ma B, Zhu H, Bai J, et al
    PI3K/Akt and Wnt/beta-catenin Signaling Cross-regulate NF-kappaB Signaling in TNF-alpha-induced Human Lgr5(+) Intestinal Stem Cells.
    Anticancer Res. 2022;42:3325-3340.
    PubMed     Abstract available

    April 2022
  7. OHASHI K, Li TS, Miura S, Hasegawa Y, et al
    Biological Differences Between Ovarian Cancer-associated Fibroblasts and Contralateral Normal Ovary-derived Mesenchymal Stem Cells.
    Anticancer Res. 2022;42:1729-1737.
    PubMed     Abstract available

    March 2022
  8. OKAMOTO A, Funakoshi Y, Oe M, Takai R, et al
    Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1.
    Anticancer Res. 2022;42:1199-1205.
    PubMed     Abstract available

    February 2022
  9. COMSA S, Ceausu AR, Popescu R, Cimpean AM, et al
    Patterns of Tumor Vasculogenesis on a Chick Embryo Chorioallantoic Membrane In Vivo Model of Breast Cancer.
    Anticancer Res. 2022;42:877-883.
    PubMed     Abstract available

    January 2022
  10. LI J, Persaud AK, Johnson JA, Sborov DW, et al
    A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy.
    Anticancer Res. 2022;42:385-395.
    PubMed     Abstract available

    December 2021
  11. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed     Abstract available

    November 2021
  12. CIERPIKOWSKI P, Lis-Nawara A, Bar J
    SHH Expression Is Significantly Associated With Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5405-5413.
    PubMed     Abstract available

  13. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    PubMed     Abstract available

    October 2021
  14. MIYAMOTO S, Fukui T, Horitani S, Tanimura Y, et al
    Linker Threonine-phosphorylated Smad2/3 Is a Biomarker of Colorectal Neoplastic Stem-like Cells that Correlates With Carcinogenesis.
    Anticancer Res. 2021;41:4789-4799.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.